Putative association of GPC5 polymorphism with the risk of inflammatory demyelinating diseases
Joong-Gon Shin1, Ho Jin Kim, Byung Lae Park
1Department of Life Science, Sogang University, Seoul, Republic of Korea.
Abstract:
Inflammatory demyelinating diseases (IDDs) are severe inflammatory diseases of the central nervous system (CNS) that cause loss of myelin in the nerve sheaths and axonal degeneration. IDDs include multiple sclerosis (MS) and neuromyelitis optica (NMO). MS affects the axons of the brain and spinal cord, while NMO primarily affects the optic nerves and spinal cord. Glypican 5 (GPC5) is known to be one of the susceptible genes for the risk of IDD, especially MS, based on genome-wide association studies (GWASs) and replication studies in Caucasians and African Americans. In the present study, in order to investigate the replicable genetic effects of GPC5 polymorphisms on the risk of IDD in Korean subjects, nine genetic variants were selected and genotyped in 237 normal controls and 178 IDD patients (including 79 MS and 99 NMO). Statistical analysis revealed that rs9523762 was associated with IDD and the association was retained even after correction for multiple testing (OR=1.68, P(corr)=0.03). Marginal association was also observed in rs1411751 (OR=0.54, P=0.02). In a subgroup analysis, rs1411751 was found to be associated with NMO (OR=0.36, P(corr)=0.03), and rs9523762 was marginally associated with both NMO and MS. These results indicate that GPC5 polymorphisms would be useful genetic indicators for IDDs, including NMO and MS.
More Related Videos
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
05:53Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets
